Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Soluble Aspirin Could Be Groundbreaking Treatment For Glioblastoma



Previous research has suggested that aspirin has anti-cancer properties, however currently-available liquid forms of the drug are not fully soluble.

Share this!

Tweet: Blood-brain barrier allows some molecules to pass into the brain http://ctt.ec/60spe+Blood-brain barrier allows some molecules to pass into the brain.

Tweet: Soluble #aspirin ten times more effective at treating #glioblastoma  http://ctt.ec/K8UT2+Soluble aspirin ten times more effective at treating glioblastoma.

July 4, 2016 | by Sarah Massey, M.Sc.

A new truly-soluble drug containing liquid aspirin, could offer a valuable treatment option for patients with a type of brain tumor known as glioblastoma. Researchers from the Brain Tumour Research Centre of Excellence at the University of Portsmouth in the United Kingdom, found that the soluble drug was able to cross the blood-brain barrier.

The blood-brain barrier is a semi-permeable membrane, which allows certain molecules to pass through, while preventing pathogens and other foreign substances from entering the brain. While this membrane is integral to protect the brain, cancer drug developers have faced numerous challenges in designing therapies that are able to pass through the barrier.

Many cancer drugs used to fight tumors in other parts of the body are too large to fit through the blood-brain barrier. Previous research has suggested that aspirin has anti-cancer properties, however currently-available liquid forms of the drug are not fully soluble. Instead, these drugs contain small particles of solid aspirin which can cause gastric side effects when taken orally.

In collaboration with Innovate Pharmaceuticals, the University of Portsmouth researchers developed the soluble drug, named IP1867B, which contains aspirin along with two other compounds. These ingredients have been show to destroy cancer cells without damaging the surrounding healthy brain tissue, and all three compounds have already been approved for clinical use.

In testing the drug on tumor cells and tissue collected from adults and children with brain cancer, the researchers found that IP1867B was ten times more effective at treating glioblastoma compared to any combination of currently-available treatments for the cancer. Glioblastoma is one of the most common and deadly forms of brain cancer in adults.

“This is a potential game-changer for research into brain tumours and clearly shows what sustainable research is able to achieve,” said Sue Farrington Smith, chief executive of Brain Tumour Research. “It is science like this that will enable us to eventually find a cure for this devastating disease which kills more children and adults under the age of 40 than any other cancer.” The researchers say that further preclinical development must be done before the soluble aspirin can enter early-stage clinical trials involving humans.

Keywords: Aspirin, Gioblastoma, Drug Delivery


Share this with your colleagues!

Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News

FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News

One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


Top 5 Most Impactful Tweets in Life Sciences During the Last Week


EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider

Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology

Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn

eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials

Copyright © 2016-2017 Honeycomb Worldwide Inc.